<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447549</url>
  </required_header>
  <id_info>
    <org_study_id>ICR-CTSU/2014/10049</org_study_id>
    <nct_id>NCT02447549</nct_id>
  </id_info>
  <brief_title>Study of Tumour Focused Radiotherapy for Bladder Cancer</brief_title>
  <acronym>RAIDER</acronym>
  <official_title>A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bladder cancer is the seventh most common cancer in the UK, with 10,399 new cases diagnosed
      in 2011. In a quarter of these cases the cancer has infiltrated the muscular wall of the
      bladder (muscle invasive) and is life threatening. This type of bladder cancer is usually
      treated either with surgical removal of the bladder, or daily radiotherapy treatment (high
      strength xrays which kill cells), given every day for 4 or 7 weeks. RAIDER will investigate
      methods which have the potential to improve how well this radiotherapy works.

      RAIDER is based on a study of novel radiotherapy techniques which was conducted at a single
      UK NHS Trust. Bladder radiotherapy is normally delivered using a single plan throughout
      treatment and treats the whole bladder with the same radiotherapy dose. In adaptive
      radiotherapy the delivery plan is chosen from 3 possible plans. In cancer (tumour) focused
      radiotherapy, the highest dose of the radiotherapy is aimed at the tumour within the bladder.

      In RAIDER, 240 participants with muscle invasive bladder cancer will be in one of 3 treatment
      groups:

        1. standard whole bladder radiotherapy

        2. standard dose tumour focused adaptive radiotherapy

        3. dose escalated tumour boost adaptive radiotherapy

      Participants will visit the hospital 4 weeks, 3, 6, 9, 12, 18 and 24 months after
      radiotherapy and annually thereafter to check whether the cancer has returned and to receive
      treatment for any symptoms they may be experiencing.

      RAIDER aims to confirm in a multicentre setting that novel techniques allow a higher
      radiotherapy dose than standard to be reliably targeted at the tumour within the bladder and
      to check that the long term side effects of the treatment are acceptable. If this is the
      case, results of RAIDER will be used to develop a study to establish whether dose escalated
      radiotherapy is better at treating bladder cancer than standard dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RAIDER has a two stage design. Stage 1 will establish the feasibility of delivering DART in a
      multi-centre setting, and stage 2 will establish the toxicity of DART. 72 patients will be
      recruited in stage 1, with an additional 168 patients in stage 2.

      Both fractionation regimens in standard use in UK are included - 32f and 20f. Participants
      will be permitted to receive concomitant chemotherapy. Primary endpoints will be assessed in
      each fractionation cohort separately with the flexibility to drop either a fractionation
      cohort or an experimental treatment group (on advice of Independent Data Monitoring
      Committee) following completion of stage 1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants meeting predefined radiotherapy dose constraints in DART group</measure>
    <time_frame>4-6 weeks from randomisation</time_frame>
    <description>Primary outcome of stage 1 of study, predefined radiotherapy dose constraints for bladder, bowel and rectum met for medium plan in DART group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients experiencing severe late side effects following radiotherapy.</measure>
    <time_frame>6-18 months post radiotherapy</time_frame>
    <description>Primary outcome of stage 2 of study, late CTC toxicity grade 3 or higher.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>WBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose whole bladder radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard dose Adaptive tumour focused radiotherapy (SART)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalated Adaptive tumour boost radiotherapy (DART)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBRT</intervention_name>
    <description>One RT plan with whole bladder treated to standard dose.</description>
    <arm_group_label>WBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SART</intervention_name>
    <description>Three plans (small, medium &amp; large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.</description>
    <arm_group_label>SART</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>DART</intervention_name>
    <description>Three plans (small, medium &amp; large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.</description>
    <arm_group_label>DART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age â‰¥16 years

          -  Histologically or cytologically confirmed transitional cell carcinoma (TCC) of the
             bladder

          -  Unifocal bladder TCC staged T2-T4a N0 M0

          -  Fit to receive a radical course of radiotherapy

          -  WHO performance status 0-2

          -  Willing and able to comply with study procedures and follow up schedule

        Exclusion Criteria:

          -  Nodal or metastatic disease

          -  Widespread carcinoma in situ (CIS) or CIS remote from muscle invasive tumour or
             multifocal invasive disease

          -  Simultaneous TCC in upper tract or urethra

          -  Pregnancy

          -  Active malignancy within 2 years of randomisation (not including non melanomatous skin
             carcinoma, previous non muscle invasive bladder tumours, NCCN low risk prostate cancer
             (T1/T2a, Gleason 6 PSA &lt;10), in situ carcinoma of any site)

          -  Any other conditions that in the Principal Investigator's opinion would be a
             contra-indication to radiotherapy (e.g. previous pelvic radiotherapy / inflammatory
             bowel disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Huddart</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Cancer Research/RMNHSFT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RAIDER Trial Manager</last_name>
    <phone>02087224295</phone>
    <email>RAIDER-icrctsu@icr.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Riverina Cancer Care Centre</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anupam Chaudhuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Pyror</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville General Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Mater Centre QLD</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kumar Gogna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marketa Skala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daryl Lim Joon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Colin Tang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chakiath Jose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steve Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roger Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tauranga</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leanne Tyrie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher Scrase</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karen Tipples</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>44-845-226-3000</phone>
    </contact>
    <investigator>
      <last_name>Ananya Choudhury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jamie Mills</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nick MacLeod</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital, Kent Oncology Centre</name>
      <address>
        <city>Adstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lees</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Darren Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anjali Zarkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, University Hospitals Birmingham NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robert Stevenson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lisa Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ashok Nikapota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology &amp; Oncology Centre</name>
      <address>
        <city>Brixton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Hillman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St Edmunds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yvonne Rimmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yvonne Rimmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Hospital, Cardiff and Vale NHS Trust</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Staffurth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Jenkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Jenkins</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Duncan McLaren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Denise Sheehan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nick MacLeod</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Luke's Cancer Centre</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Khaskar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ann Henry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Hughes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHSFT</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Huddart</last_name>
    </contact>
    <investigator>
      <last_name>Robert Huddart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHSFT</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincent Khoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anita Mitra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Oldham Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Conroy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Kent Hospitals University NHS Foundation Trust</name>
      <address>
        <city>Margate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Carys</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Care, Freeman Hospital,</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Frew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood, Middlesex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Alonzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gaurav Kapur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peterborough City Hospital</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah Treece</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoodvhir Nagar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alison Birtle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Hospital, Barking Havering and Redbridge University Hospitals NHS Trust</name>
      <address>
        <city>Romford, Essex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephanie Gibbs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital, Sheffield Teaching Hospitals Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Furguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton NHS Foundation Trust</name>
      <address>
        <city>Stadhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harish Reddy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital, Sherwood Forest Hospitals Foundation NHS Trust</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Saunders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust</name>
      <address>
        <city>Taunton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohini Varughese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torbay District General Hospital</name>
      <address>
        <city>Torbay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Lydon</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Yorkshire Hospitals</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sree Rodda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinderfields hospital, The Mid Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Wakefield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sree Rodda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabel Syndikus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Oldham Hospital</name>
      <address>
        <city>Yeldham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Conroy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMRT</keyword>
  <keyword>IGRT</keyword>
  <keyword>Muscle invasive</keyword>
  <keyword>Adaptive Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

